{"organizations": [], "uuid": "21cc9c37ac696229df8de9355ff0e8af4f2f8552", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180523.html", "section_title": "Archive News &amp; Video for Wednesday, 23 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-esperion-announces-third-pivotal-p/brief-esperion-announces-third-pivotal-phase-3-study-of-bempedoic-acid-meets-primary-endpoint-idUSFWN1SU0SD", "country": "US", "domain_rank": 408, "title": "BRIEF-Esperion Announces Third Pivotal Phase 3 Study Of Bempedoic Acid Meets Primary Endpoint", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.875, "site_type": "news", "published": "2018-05-23T21:27:00.000+03:00", "replies_count": 0, "uuid": "21cc9c37ac696229df8de9355ff0e8af4f2f8552"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-esperion-announces-third-pivotal-p/brief-esperion-announces-third-pivotal-phase-3-study-of-bempedoic-acid-meets-primary-endpoint-idUSFWN1SU0SD", "ord_in_thread": 0, "title": "BRIEF-Esperion Announces Third Pivotal Phase 3 Study Of Bempedoic Acid Meets Primary Endpoint", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "esperion therapeutics inc", "sentiment": "negative"}, {"name": "esperion", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 23 (Reuters) - Esperion Therapeutics Inc:\n* ESPERION ANNOUNCES THIRD PIVOTAL PHASE 3 STUDY OF BEMPEDOIC ACID MEETS PRIMARY ENDPOINT\n* ESPERION - STUDY 3 ACHIEVES ADDITIONAL 26% LDL-C LOWERING ON BACKGROUND OF MAXIMALLY TOLERATED LDL-C LOWERING THERAPY IN PATIENTS CONSIDERED STATIN INTOLERANT\n* ESPERION THERAPEUTICS INC - CUMULATIVE PHASE 2 / PHASE 3 DEMONSTRATES BROAD EFFICACY AS WELL AS SAFETY AND TOLERABILITY Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-23T21:27:00.000+03:00", "crawled": "2018-05-24T20:14:52.000+03:00", "highlightTitle": ""}